Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
25.21
-0.40 (-1.56%)
At close: Aug 31, 2026, 4:00 PM EDT
25.20
-0.01 (-0.04%)
Pre-market: Sep 1, 2026, 4:00 AM EDT
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
According to 20 analysts polled by S&P Global, Ultragenyx Pharmaceutical stock has a consensus rating of "Strong Buy" and an average price target of $55.05. The average 1-year stock price forecast is 118.37% higher than the current stock price, while the lowest is $28 (+11.07%) and the highest is $103 (+308.57%).
Price Target: $55.05 (+118.37%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 13 | 12 | 12 | 12 | 13 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 19 | 19 | 19 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Reiterates $46 → $50 | Buy | Reiterates | $46 → $50 | +98.33% | Aug 28, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $75 → $80 | Buy | Reiterates | $75 → $80 | +217.33% | Aug 25, 2026 |
Unknown Analyst Jefferies No rating | Jefferies | Buy Maintains $77 | Buy | Maintains | $77 | +205.43% | Aug 21, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $67 → $74 | Buy | Reiterates | $67 → $74 | +193.53% | Aug 21, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $46 → $48 | Buy | Reiterates | $46 → $48 | +90.40% | Aug 21, 2026 |
Financial Forecast
Revenue This Year
762.63M
from 673.00M
Increased by 13.32%
Revenue Next Year
1.01B
from 762.63M
Increased by 32.34%
EPS This Year
-3.85
from -5.83
EPS Next Year
0.67
from -3.85
EPS and Forward PE are based on non-GAAP adjusted numbers.